Clinical trials
Lung Fibrosis Interstitial clinical trials
Below are recruiting lung fibrosis interstitial clinical trials, each written for real people, not researchers. We’re tracking 80 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07473700RecruitingPhase 2
Study of TX000045 for lung scarring and high blood pressure in the lungs
This trial tests a new medicine called TX000045 for people who have both lung scarring (interstitial lung disease) and high blood pressure in the lungs (pulmonary hypertension). It aims to see if the drug can help improve breathing and daily function.
Phoenix, ArizonaAges 18–80 - NCT06987266Recruiting
Study of lung and airway disease diagnosis
This study aims to improve how doctors diagnose and classify lung conditions that affect both the air sacs and airways, such as COPD and pulmonary fibrosis. By participating, you may help advance medical knowledge and better understand your own condition.
Changsha, HunanAges 40–80 - NCT06815185Recruiting
Counseling help for people with interstitial lung disease
This study tests a counseling program to help people with interstitial lung disease (a group of lung conditions that cause scarring and make breathing harder) with rehabilitation and support. It may help you cope better and stay active.
Bologna, BolognaAges 18 years+ - NCT06549231RecruitingPhase 3
Rituximab and mycophenolate for scleroderma lung disease
This trial tests whether combining two drugs, rituximab and mycophenolate mofetil, is safe and works better than standard care for lung scarring caused by scleroderma. It may be an option if your lung disease is severe or getting worse.
ToursAges 18–100 - NCT02852928Recruiting
ChILD-EU registry for childhood lung disease samples
This trial builds a European “registry and biobank” of children with suspected or confirmed interstitial lung disease (a type of lung problem), as well as conditions that can look similar. It helps researchers learn more about these rare childhood lung diseases and connect families to future studies.
Hanover, Lower SaxonyAges Any age - NCT07366034RecruitingPhase 3
Testing nerandomilast for children with lung scarring
This trial tests a new oral medicine, nerandomilast, to see if it helps children and teens (ages 2 to under 18) who have a type of lung disease that causes scarring (interstitial lung disease). The study monitors how well patients tolerate the drug and whether it improves their breathing.
Los Angeles, CaliforniaAges 2–17 - NCT06388421Recruiting
PH-ILD patient registry: tracking real-world outcomes
This study tracks people with both lung scarring and high blood pressure in the lungs (Group 3 PH-ILD) to better understand the disease and how treatments like Tyvaso work in real life. It may help you and your doctor make more informed decisions about your care.
Birmingham, AlabamaAges 18 years+ - NCT07541638Recruiting
Early Lung Fibrosis Detection in Rheumatic Diseases
This study helps doctors identify early signs of lung scarring (fibrosis) in patients with autoimmune diseases like scleroderma, rheumatoid arthritis, and Sjögren's syndrome. By catching this early, researchers hope to better understand and treat these complications.
RomaAges 18–75 - NCT07179380RecruitingPhase 3
Inhaled treprostinil for pulmonary hypertension related to interstitial lung disease
This study tests an inhaled powder medication called TPIP (treprostinil palmitil inhalation powder) to see if it can improve symptoms and exercise ability in people who have both interstitial lung disease and pulmonary hypertension. The study will compare TPIP against a placebo (a dummy treatment without the active drug) to understand how well it works and if it is safe.
Phoenix, ArizonaAges 18 years+ - NCT07540988RecruitingPhase 3
Testing Nerandomilast for Scarring Lung Disease
This study tests whether a new drug called nerandomilast can slow down scarring in the lungs for people with certain types of fibrosing interstitial lung disease (a condition where lung tissue becomes thick and scarred). You may qualify if you have lung scarring that is getting worse and haven't tried this or similar drugs before.
Birmingham, AlabamaAges 18 years+ - NCT07234032RecruitingPhase 3
Long-term follow-up study of TPIP for PH-ILD
This trial is a long-term follow-up study for people who already completed a previous study of an inhaled treprostinil medication (TPIP) for pulmonary hypertension caused by interstitial lung disease (PH-ILD). It tests whether continued treatment with TPIP is safe and effective over a longer period.
Naples, FloridaAges 18 years+ - NCT07174102Recruiting
Looking at lung scans in rheumatoid arthritis and related diseases
This trial studies lung scans (HRCT) from patients with rheumatoid arthritis, interstitial lung disease, or connective tissue disease to better understand lung involvement. If you have one of these conditions and have had a lung CT, you may be able to help.
PragueAges 18 years+ - NCT07613099RecruitingPhase 3
Testing a new PET scan to detect lung and heart scarring
This study tests a new imaging scan (called 18F-FAPI PET/CT) that may help detect scarring in the lungs, heart, or blood vessels. If you have a heart, lung, or blood vessel condition that could cause scarring, this scan might show damage earlier and help doctors plan better treatment.
Bethesda, MarylandAges 18–100 - NCT03535545RecruitingPhase 1
PET-MRI imaging test in lung cancer and lung disease
This Phase 1 study tests a radioactive imaging agent to help doctors see disease activity in the lungs using PET/MRI scans. It includes healthy volunteers and people with lung cancer, idiopathic pulmonary fibrosis, lung transplant–related lung problems, or certain medication-related lung inflammation.
Boston, MassachusettsAges 18–80 - NCT06476470Recruiting
Taiwan ILD registry for understanding lung disease
This registry is gathering information from people with different types of interstitial lung disease (ILD) across Taiwan. It aims to better understand the disease and improve future care.
TaichungAges 18 years+ - NCT07333183RecruitingPhase 2
Mosliciguat plus treprostinil for lung disease with pulmonary hypertension
This trial tests a new medicine called mosliciguat combined with an inhaled treatment (treprostinil) for people who have both scarring lung disease (interstitial lung disease) and high blood pressure in the lungs. It aims to see if this combination can improve how well you feel and function.
Santa Barbara, CaliforniaAges 18–85 - NCT05727852Enrolling by invitation
Breath and heart tests to study lung disease stiffness
This study uses breath analysis and heart/electrical heart testing to look at how stiff the arteries are in people with long-term lung conditions. It may help researchers better understand lung disease effects on the cardiovascular system.
MoscowAges 18 years+ - NCT06036719Recruiting
Lung scarring study from childhood to old age
This trial looks at different types of lung scarring (called interstitial lung disease) to better understand the condition across all ages. It also includes family members of people with certain genetic mutations that affect the lungs.
Paris, Île-de-France RegionAges Any age - NCT07254338Recruiting
Blood chemicals study in lung scarring and high lung blood pressure
This study looks at special chemicals in the blood (metabolites) from people with both lung scarring and high lung blood pressure. It aims to learn how these chemicals change with or without treatment for the lung blood pressure.
Bron, RhoneAges 18 years+ - NCT07175038RecruitingPhase 2
Study of a new pill for pulmonary hypertension
This study tests a new pill, ROC-101, for people with pulmonary hypertension (high blood pressure in the lungs). It aims to see if the pill can improve symptoms and daily function.
Phoenix, ArizonaAges 18–80 - NCT05819385Recruiting
Study of lung scarring in immune diseases
This is an observational (non-treatment) study that collects information about how interstitial lung disease (lung scarring) happens in people with certain autoimmune or immune-related conditions. It uses patient interviews or existing medical records to better understand the pattern and causes, which may help future care.
Mexico CityAges 18 years+ - NCT07816185RecruitingPhase 3
Inhaled study drug for pulmonary hypertension with lung scarring
This study tests an inhaled medication called mosliciguat for people with pulmonary hypertension (high blood pressure in the lungs) caused by certain types of lung scarring. It may help improve your ability to exercise and manage symptoms.
Kissimmee, FloridaAges 18–85 - NCT07300696Recruiting
MRI to track lung disease changes in ILD
This study uses MRI scans to monitor how lung scarring changes over time in people with certain types of interstitial lung disease (ILD), like idiopathic pulmonary fibrosis (IPF). The goal is to see if MRI can be a helpful tool for tracking the disease without needing as many CT scans.
HeidelbergAges 18 years+ - NCT03437486Recruiting
Family study for inherited lung scarring causes
This study looks at what causes familial (inherited) pulmonary fibrosis by studying relatives who are not yet diagnosed with the lung disease. You may help researchers understand risk and early changes in the lungs within families.
Nashville, TennesseeAges 40–75
Hear when a new Lung Fibrosis Interstitial trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung fibrosis interstitial?
- Yes. Clin2 currently lists 80 recruiting lung fibrosis interstitial studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung fibrosis interstitial trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung fibrosis interstitial trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.